Climb Bio (CLYM) Projected to Announce Earnings on Wednesday

Climb Bio (NASDAQ:CLYM) will likely be releasing its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Climb Bio to announce earnings of ($0.20) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.03. On average, analysts expect Climb Bio to post ($0.80) EPS for the current fiscal year and ($1.01) EPS for the next fiscal year.

Climb Bio Stock Performance

CLYM stock opened at $9.75 on Wednesday. The firm has a market cap of $560.04 million, a P/E ratio of -11.75 and a beta of 0.01. The firm’s fifty day moving average is $12.32 and its 200 day moving average is $10.39. Climb Bio has a 52 week low of $1.63 and a 52 week high of $18.33.

Analysts Set New Price Targets

CLYM has been the topic of a number of recent research reports. Mizuho raised Climb Bio to a “strong-buy” rating in a research note on Wednesday, September 16th. Robert W. Baird boosted their target price on Climb Bio from $21.00 to $25.00 and gave the company an “outperform” rating in a research note on Thursday, September 3rd. Wedbush reissued an “outperform” rating and issued a $20.00 target price on shares of Climb Bio in a research note on Wednesday, August 19th. Oppenheimer raised their price target on Climb Bio from $18.00 to $25.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 8th. Finally, Guggenheim restated a “buy” rating on shares of Climb Bio in a research report on Monday, October 26th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Climb Bio presently has a consensus rating of “Buy” and an average target price of $27.64.

Insider Transactions at Climb Bio

In other Climb Bio news, Director Stephen Thomas sold 100,000 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $13.67, for a total value of $1,367,000.00. Following the transaction, the director owned 467,969 shares in the company, valued at approximately $6,397,136.23. The trade was a 17.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.60% of the stock is currently owned by company insiders.

Climb Bio Company Profile

Climb Bio, Inc (NASDAQ: CLYM) is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. The company is working to create medicines that target B cells, which play a central role in the immune responses associated with many autoimmune disorders.

Climb Bio’s lead investigational product, CLYM116, is a fully human anti-CD19 monoclonal antibody designed to selectively deplete B cells. The therapy is being evaluated in clinical development for autoimmune conditions, including primary membranous nephropathy, a kidney disorder in which abnormal immune activity can damage the kidneys.

As a development-stage biotechnology company, Climb Bio’s activities are centered on research, clinical trials and the potential commercialization of its pipeline rather than on marketed products.